PUBLISHER: Stratistics Market Research Consulting | PRODUCT CODE: 1865451
PUBLISHER: Stratistics Market Research Consulting | PRODUCT CODE: 1865451
According to Stratistics MRC, the Global Automation in Solid and Liquid Dosage Pharmaceutical Manufacturing Market is accounted for $7.0 billion in 2025 and is expected to reach $15.0 billion by 2032 growing at a CAGR of 11.5% during the forecast period. Automation in pharmaceutical manufacturing involves using control systems to operate equipment for producing solid (tablets, capsules) and liquid (syrups, injections) dosage forms with minimal human intervention. It encompasses processes like dispensing, mixing, granulation, compression, filling, and packaging. This enhances precision, efficiency, and compliance with stringent regulations. By ensuring consistent product quality, reducing contamination risks, and improving batch traceability, automation is vital for scaling up production and maintaining Good Manufacturing Practice (GMP).
According to Springer's Therapeutic Innovation & Regulatory Science journal, artificial intelligence is transforming liquid dosage formulation by enabling data-driven optimization. AI improves efficiency in drug discovery, formulation, and manufacturing, reducing reliance on trial-and-error methods
Rising demand for production efficiency
The increasing focus on improving production efficiency is propelling automation adoption in solid and liquid dosage pharmaceutical manufacturing. Fueled by the growing need to minimize manual intervention, enhance precision, and optimize throughput, manufacturers are investing in advanced automated systems. Automation solutions streamline operations, reduce cycle times, and ensure consistent quality, particularly in complex dosage formulations. Moreover, the integration of robotics and AI-driven control systems enhances process reliability, ensuring compliance with regulatory standards and scalability in pharmaceutical output.
High initial capital investment
Despite its benefits, high upfront investment acts as a key barrier to widespread automation deployment in pharmaceutical dosage manufacturing. The integration of robotics, vision inspection, and digital monitoring technologies requires significant capital, particularly for small and mid-sized firms. Additionally, customization and validation costs further elevate financial burdens. Spurred by stringent compliance requirements and maintenance complexities, many firms delay automation adoption. Consequently, the return on investment period extends, limiting faster technological penetration across developing pharmaceutical production environments.
Growth in personalized medicine packaging
The emergence of personalized medicine is unlocking lucrative automation opportunities in pharmaceutical manufacturing. As customized dosage forms and patient-specific therapies gain traction, automated packaging and dosing systems ensure precision and flexibility. Advanced robotics and adaptive control technologies enable batch-level customization and real-time adjustments. Driven by the demand for individual-centric drug delivery, automation helps reduce errors, enhance traceability, and streamline small-batch production. Consequently, pharmaceutical players are adopting digital automation to support the scalability of personalized and precision-based drug packaging processes.
Supply chain disruptions impact automation
Global supply chain disruptions pose a substantial threat to automation-driven pharmaceutical manufacturing. Interruptions in semiconductor availability, equipment logistics, and component shortages hinder system integration and commissioning. Moreover, dependency on specialized vendors for automation components amplifies vulnerability during geopolitical tensions. Spurred by fluctuating material costs and delayed installations, production continuity risks rise. Hence, companies increasingly focus on regionalized sourcing strategies and resilient supplier networks to mitigate automation downtime and maintain operational reliability in dosage manufacturing lines.
The COVID-19 pandemic accelerated automation adoption across solid and liquid dosage manufacturing due to heightened demand for uninterrupted production. Fueled by labor shortages and social distancing norms, companies turned to robotic handling and automated inspection systems. Additionally, remote monitoring and digital twin technologies supported predictive maintenance and quality control. However, initial lockdowns delayed equipment procurement and installation. Over time, the crisis reinforced the strategic necessity for automation, transforming production agility and reinforcing resilience across pharmaceutical manufacturing workflows.
The solid dosage form automation segment is expected to be the largest during the forecast period
The solid dosage form automation segment is expected to account for the largest market share during the forecast period, propelled by its extensive application in tablet compression, coating, and packaging operations. Manufacturers are emphasizing precision and repeatability in large-scale tablet production, driving automation uptake. Fueled by demand for consistency and compliance, automated systems enhance throughput and quality control. Additionally, the segment benefits from increasing investments in robotic dispensing, automated filling, and inspection units that reduce operational variability.
The primary packaging automation segment is expected to have the highest CAGR during the forecast period
Over the forecast period, the primary packaging automation segment is predicted to witness the highest growth rate, influenced by rising requirements for product safety and contamination prevention. Driven by stringent regulatory mandates, automated primary packaging systems enhance sealing precision and minimize human contact. Furthermore, the growing shift toward blister, sachet, and vial packaging for both solid and liquid dosage forms accelerates adoption. Integration of machine vision and AI ensures labeling accuracy and traceability, boosting this segment's expansion trajectory.
During the forecast period, the Asia Pacific region is expected to hold the largest market share, fuelled by rapid pharmaceutical manufacturing expansion in China, India, and South Korea. Government incentives supporting industrial automation and investments in advanced production facilities bolster growth. Additionally, rising generics output and contract manufacturing activities enhance automation integration. The region's growing pool of skilled engineers and cost-effective deployment environments further strengthen its leadership in automated solid and liquid dosage manufacturing adoption.
Over the forecast period, the North America region is anticipated to exhibit the highest CAGR, driven by strong digital transformation initiatives and early technology adoption among major pharmaceutical firms. The region's established regulatory framework encourages process validation through automation. Additionally, increasing investments in smart factories and data-driven manufacturing enhance production agility. Fueled by a growing focus on personalized medicine and stringent FDA compliance, automation uptake continues to surge across U.S. and Canadian dosage production facilities.
Key players in the market
Some of the key players in Automation in Solid and Liquid Dosage Pharmaceutical Manufacturing Market include Siemens, Rockwell Automation, Bosch Packaging, Syntegon, Korber Pharma, Becton Dickinson, IMA Group, Marchesini, OPTIMA Packaging, Uhlmann Pac-Systeme, Omnicell, ARxIUM, Yuyama Co., Ltd., Mitsubishi Electric, Honeywell, GEA Group, Thermo Fisher, and Schneider Electric.
In September 2025, Siemens and Merck extended their strategic partnership to accelerate digital transformation in pharmaceutical manufacturing. The collaboration aims to integrate Merck's SaaS products with Siemens' digital ecosystem, deploying AI tools for smarter, faster drug development using technology from Siemens' July 2025 Dotmatics acquisition.
In October 2025, Rockwell Automation launched the ControlLogix 5590 Controller, a next-generation platform designed for advanced industrial and pharmaceutical automation, featuring integrated safety and multidiscipline control for streamlined manufacturing.
In May 2025, Syntegon premiered its SynTiso line for automated liquid pharmaceutical filling, developed in direct collaboration with two major pharmaceutical partners, to enhance automation and yield while reducing operator intervention.
Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.